R & D is SIAL’s most important activity and involves collaborations with mainly pharmaceutical and biotechnological companies
SIAL focuses on the initial studies performed in experimental models aimed at determining both the functionality and safety of new chemical entities and products in development in biotechonolgical and pharmaceutical industry as well as medical devices.
SIAL’s strategic niche lies in two main areas: flexibility of approach and comprehensive service.
Our laboratory works in accordance with Quality Standards (but not GLPs) revised by the Quality Assurance Unit of the UAB. This gives us greater flexibility in the early stage of drug development and other biomedical products where flexibility in experimentation is required. At the same time, the study will be done accordingly to the high-quality standards according to the requirements required for Registry of the product.
Our services are particularly useful for researchers and technology based companies which do not have the facilities and staff required to perform tests for assessing the activity of the products they are developing in animal models. Our services help these companies to save time and resources because they allow them to establish protocols and dosage before going to a CRO to undertake security studies required by governmental agencies for registration in the case of pharmaceutical drugs and biologicals. In the case of medical devices, our studies are performed ready for registration.
In the last five years we have carried out studies for the following companies: ASCIL Biopharm S.L.; Bbraun Surgical S.A.; Bioibérica S.A.; Grupo Ferrer Internacional, S.A.; Histocell S.L.; Labiana Pharmacuticals, S.L.U.; NEOS Surgery S.L.; Noscira S.A.; SERGAS; Sylentis S.A.; XCELIA-Banc de Sang i Teixits; ZERA INTEIN PROTEIN SOLUTIONS S.L.
We are also collaborating with some of these companies on research studies funded by the Spanish Ministry of Science and Innovation (CENIT/MICINN).